Genmab A/S at TD Cowen Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Yaron Werber - TD Cowen - Analyst : So Anthony, maybe for you, as you're thinking about, you've talked a lot about P&L and the strategy about how you invest in the pipeline, how you grow the top line. You have a lot of pipeline also in early development and I think you're also looking still for maybe external innovation as well. So as you're thinking about it, balancing earnings growth or margins versus investment, what comes to mind?

Question: Yaron Werber - TD Cowen - Analyst : And do you have room to bring in another externally derived asset into late stage in P&L room?

Question: Yaron Werber - TD Cowen - Analyst : And you just renegotiated your agreement or you changed a little bit of the primary responsibility in TIVDAK. How does that tie into also strategically right to EPKINLY in your co-marketing with, Anthony?

Question: Yaron Werber - TD Cowen - Analyst : Yeah, TIVDAK (multiple speaker) REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 03, 2025 / 6:50PM, GMAB.CO - Genmab A/S at TD Cowen Healthcare Conference

Question: Yaron Werber - TD Cowen - Analyst : Lay down commercial ops in Europe. I imagine you're going to do it in a scaled kind of version, right, based on upcoming approvals and upcoming launches and reimbursements.

Question: Yaron Werber - TD Cowen - Analyst : Maybe there's a lot of talk about on the pipeline, but I do want to maybe ask one question on 3014. I think J&J has -- is it -- I think it was 60 days from when they accepted, so essentially this week or next week to hear a decision. Is my timing sort of correct? And then secondly, from everything you've said, and I think some of the things they've said, it sounds like increasingly likely that you're obviously designing your business with the assumption that they're probably not going to -- that's upside to your plan. Is that sort of fair and, it -- the writing on the wall is that, we're all expecting that they're probably not going to bring that forward. I don't know if you can comment at all.

Question: Yaron Werber - TD Cowen - Analyst : And no matter what the decision is at that point, you will release the data and outline next steps, or they will release the data and outline next steps.

Question: Yaron Werber - TD Cowen - Analyst : Actually, maybe I'll -- let me -- I'll proceed next and I'll turn it over to Jane on EPKINLY. Julie, maybe a couple of questions for you. There's going to be a lot of data coming next year, right? 3 Phase, 3 studies with the EPKINLY across both DLBCL and FL. Maybe, do you have a sense how that data is going to come out, which study you think might come first just based on enrollment and your expectations?

Question: Yaron Werber - TD Cowen - Analyst : And when you think Judith on the cadence, I mean the second line follicular that's Epcor plus or minus R squared, right?

Question: Yaron Werber - TD Cowen - Analyst : Maybe just to orient everybody there's a first line DLBCL study EPCORE with R-CHOP, and then there's a second line DLBCL study Epcor, head to head against the end of the care. They're all -- the primary is PFS.

Question: Yaron Werber - TD Cowen - Analyst : And to file on the primary, that's co-primary and PFS and survival, do you need mature survival data or can you file with a trend on OS.

Question: Yaron Werber - TD Cowen - Analyst : Right. And do you have sufficient power in the second setting for OS.

Question: Yaron Werber - TD Cowen - Analyst : And are patients allowed to do crossover once they hit PFS?

Question: Yaron Werber - TD Cowen - Analyst : In the second setting once you hit the PFS, can there is a crossover?

Question: Yaron Werber - TD Cowen - Analyst : So patients will go on to the next best supportive (inaudible).

Question: Yaron Werber - TD Cowen - Analyst : And can they -- are they theoretically they can go into a CAR-T at that point.

Question: Yaron Werber - TD Cowen - Analyst : Okay. Got it. The -- and maybe just a quick question about commercially right now, how has the uptake been in follicular since the approval?

Question: Yaron Werber - TD Cowen - Analyst : And are most physicians following the label and treating through progressions, or are they doing fixed duration or is it going to be a combination?

Question: Yaron Werber - TD Cowen - Analyst : And I think that maybe the last question on EPKINLY, you're also studying outpatient dosing. And can you talk about what those studies, and I think outpatient is now your standard right in all future studies and ongoing studies. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 03, 2025 / 6:50PM, GMAB.CO - Genmab A/S at TD Cowen Healthcare Conference

Question: Yaron Werber - TD Cowen - Analyst : Okay. Jane, over to you.

Question: Yaron Werber - TD Cowen - Analyst : CD70, are you looking at, I imagine you're not looking at AML. I imagine you're looking at solid tumors.

Question: Yaron Werber - TD Cowen - Analyst : And how do you decide or back maybe then, how did the Profound decide whether to use an MME or Topo or a different payload.

Question: Yaron Werber - TD Cowen - Analyst : -- minus what the royalty rate that you're do on Mim8.

Question: Yaron Werber - TD Cowen - Analyst : Is it graded or it's fairly flat?

Question: Yaron Werber - TD Cowen - Analyst : Terrific. Judith, thank you for coming. I owe you an apology. I think I called you Julie. I'm so sorry. It's great to see you. Thank you for joining and Anthony, thank you for joining. I really appreciate.